Polypharmacy with anticonvulsants: Focus on synergism

CNS Drugs

Volumn 8, Issue 5, 1997, Pages 366-375

  Leach, John Paul ^a  

^a WALTON CENTRE FOR NEUROLOGY AND NEUROSURGERY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

4 AMINOBUTYRIC ACID; ANTICONVULSIVE AGENT; BARBITURIC ACID DERIVATIVE; BENZODIAZEPINE DERIVATIVE; CARBAMAZEPINE; GABAPENTIN; GLUTAMIC ACID; GLUTAMINE; LAMOTRIGINE; OXCARBAZEPINE; PENTETRAZOLE; PHENYTOIN; TIAGABINE; TOPIRAMATE; VALPROIC ACID; VIGABATRIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTICONVULSANT THERAPY; CONTROLLED STUDY; DOSE RESPONSE; DRUG MECHANISM; DRUG METABOLISM; DRUG MIXTURE; DRUG POTENTIATION; EPILEPSY; HUMAN; MOUSE; NONHUMAN; PRIORITY JOURNAL; REVIEW;

EID: 0030775963     PISSN: 11727047     EISSN: None     Source Type: Journal    
DOI: 10.2165/00023210-199708050-00003     Document Type: Review

References (76)

1. Goodridge DMG, Shorvon SD. Epileptic seizures in a population of 6000. I: Demography, diagnosis and classification. BMJ 1983; 287: 641-4
2. Goodridge DMG, Shorvon SD. Lpileptic seizures in a population of 6000. 2: Treatment and prognosis. BMJ 1983; 287: 645-7
3. Shorvon SD. Epidemiology, classification, natural history, and genetics 0f epilepsy. Lancet 1990; 336: 93-6
4. Brodie MJ, Dichter M. Anticonvulsant drugs. N Engl J Med 1996; 334: 168-75
5. Leach JP, Brodie MJ. New antiepileptic drugs: an explosion of activity. Seizure 1995; 4: 5-17
6. Reynolds LH. Changing view of the prognosis of epilepsy BMJ 1990; 301: 1112-4
7. Dichter MA, Brodie MJ. The new antiepileptic drugs. N Engl J Med 1996; 334: 1583-90
8. Mattson RH, Cramer JA, Collins JF, et al. Comparison of phenobarbital, phenytoin and primidone in partial and secondary generalised tunic-clonic. N Engl J M 1985; 313: 145-51
9. Mattson RH. Effects of established and new antiepileplic drugs. Lpilepsia 1995; 36 Suppl. 2: 13-26
10. Walker MC, Sander JWAS. The impact of new antiepileptic drugs on the prognosis of epilepsy: seizure freedom should be the ultimate goal. Neurology 1996; 46: 912-4
11. Brodie MJ, Richens A, Yuen AWC. Double-blind comparison of lamotrigmc and carbamazepine in newly diagnosed epilepsy. Lancet 1995; 345: 476-9
12. Mawei GL, Pleuvry BJ. Interactions involving new antiepileptic drugs. Pharmacol Ther 1995; 68: 209-31
13. Brodie MJ. Drug interactions and epilepsy. Lpilcpsia 1992; 33: 13-22
14. Koller WC, Silver DE, Lieberman A. An algorithm for the management of PD. Neurology 1994; 44 Suppl. 10: 1-51
15. Shorvon SD, Reynolds LH. Unnecessary polypharmacy for epilepsy. BMJ 1977; 1: 1635-7
16. Shorvon SD, Reynolds LH. Reduction of polypharmacy for epilepsy. BMJ 1979; 2: 1023-5
17. Reynolds LH, Shorvon SD. Monotherapy or polytherapy for epilepsy. Epilepsia 1981; 22: 1-10
18. Schmidt D, Gram L. Monotherapy versus polytherapy in epilepsy. CNS Drugs 1995; 3: 194-208
19. Verity CM, Hosking G, Easter DJ. A multicentre comparative trial of sodium valproate and carhamazepine in paediatrie epilepsy. Dev Med Child Neurol 1995; 37: 97-108
20. Kalviainen R, Aikia M, Saukkonen AM, et al. Vigahalrin versus carhamazepine monotherapy in patients with newly diagnosed epilepsy: a randomized. controlled study. Arch Neurol 1995; 52: 989-46
21. Covauis A, Gupta AK, Jcavons PM. Sodium valproate: monotherapy and polytherapy. Hpilepsia 1982; 23: 693-720
22. Chadwick DW. Diagnosis of epilepsy. Lancet 1990; 336: 291-5
23. Loiseau P. Benign local epilepsies of childhood. In: Wyllie E, editor. The Irealment of epilepsy: principles and practice. Philadelphia: Lea and Fehiger. 1993: 584-94
24. Diilac O, NGuyen T. The Lennox (iastaut syndrome. Hpilepsia 1993; 34Suppl. 7: 7-17
25. Schmidt D, Haenel F. Therapeutic plasma levels of phenytoin. phenobarbital, and carbamazepinc: individual variation in relation to seizure frequency and type. Neurology 1984; 34: 1252-5
26. Schmidt D. Single drug therapy for intractable epilepsy. J Neurology 1983; 229: 221-6
27. McKee PJW, Blacklaw J, Butler E, et al. Monotherapy with conventional and conllolled-release carbamazepinc: a double-blind, double-dummy comparison in epileptic patients. Br J Clin Pharmacol 1991; 32: 99-104
28. Persson LI, BenMenachem H, Bengtsson H, et al. Differences in side effects between a conventional carbainazepine preparation and a slow release preparation of carbamazepine. Epilepsy Kes 1990; 6: 137-40
29. Imaizumi T, Izumi T, Hukuyama Y. A comparative clinical and pharmacokinctic study of a new slow release versus conventional forms of valproic acid in children with epilepsy. Brain Dev 1992; 14: 304-8
30. Hakkareincn H. Carbamazepine versus phenytoin rv their combination in refractory epilepsy [abstract]. Neurology 1980; 30: 354
31. Dean JC, Penry JK. Carhamazepine/valproate therapy in 100 patients with partial seizures failing carbamazepine monoiherapy: long term follow up [abstract]. Epilepsia 1988; 29: 687
32. Nakane Y, Okuina T, Takashi R, et al. Multi-institutional study of the teratogenicity and fetal toxicity of antiepileptic drugs: a report of a collaborative study group in Japan. Epilepsia 1980; 21: 663-80
33. Bcghi L, Di Mascio R, Tognoni G. Drug treatment of epilepsy: outlines, criticism and perspectives. Drugs 1986; 31: 249-65
34. Lammers MW, Hekster YA, Keyser A, et al. Monotherapy or polytherapy for epilepsy revisited: a quantitative assessment. Hpilepsia 1995; 36: 440-6
35. Pritchard JW, Ransom BR. Phenobarbital - mechanisms of action. In: Levy RH, Malison RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 359-70
36. Delorenzo RJ. Phenytoin mechanisms of action. In: Levy RH, Mattson RH, Mcldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 271-2
37. Meldrum BS. Update on mechanism of action of antiepileptic drugs. Hpilepsia 1996; 37 Suppl. 6: 4-11
38. MacDonald RL. Carbamazepine - mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 491-8
39. Haricllo RG, Varasi M, Smith MC. Sodium valproale - mechanisms of action. In: Levy RH, Malison RH, Meldrum BS, editors. Atitiepileptic drugs. 4th ed. New York: Raven Press. 1995: 581-8
40. MacDonald RL. Benzodiazepines - mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs 4th ed. New York: Raven Press. 1995: 695-703
41. Jung MJ, Palfreyman MG. Vigabatrin - mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, editors. Anliepileptic drugs. 4th ed. New York: Raven Press. 1995: 903-13
42. Leach MJ, Lees G, Riddall DR. Lumotrigine - mechanisms of action. In: Levy RH, MattsonRH. Meldrum BS, editors. Antiepileplic drugs. 4th ed. New York: Raven Press, 1995: 861-9
43. Taylor CP. Gabapentin - mechanisms of action. In: Levy RH, Malison RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 829-41
44. Shank RP, Gardocki JF, Vaught JL, et al. Topiramale: preclinical evaluation of a structurally novel anticonvulsanl. Fpilepsia 1994; 35: 450-60
45. Wilder BS. The treatment of epilepsy: an overview of clinical practices. Neurology 1995; 45 Suppl. 2: 7-11
46. Rogawski M, Porter R. Antiepileptic drugs: pharmacological mechanisms and clinical efficacy with consideration of promising developmental stage compounds. Pharmacol Rev 1990; 42: 223-86
47. Dam M, Oslergaard LH. Potential antiepileptic drugs - oxcarbazepine. In: Levy RH, Malison RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press, 1995: 987-96
48. Nielsen EB, Suzdak PD, Andersen KE, et al. Characterisation of tiagabine, a new potent and selective GABA uptake inhibitor. Eur J Pharmacol 1991; 196: 257-66
49. Ostergaard LH, Gram L, Dam M. Potential antiepileptic drugs - tiagahine. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileptic drugs. 4th ed. New York: Raven Press. 1995: 1057-62
50. Taylor CP. Mechanism of action of new antiepileptic drugs. In: Chadwick D, editor. New trends in epilepsy management: the role of gabapentin. London: Royal Society of Medicine Services, 1993: 13-40
51. MacDonald RL, Kelly KM. Antiepileptic drug mechanisms of action. Epilepsia 1995; Suppl. 2: 2-12
52. Chez MG, Bourgeois BF, Pippenger GE, et al. Pharmacodynamic interactions between phenytoin and vulproate: individual and combined antiepileptic and neurotoxic actions in mice. Clin Neuropharmacol 1994; 17: 32-7
53. Bourgeois BF. Anticonvulsant potency and neurotoxicity of valproate alone and in combination with carhamazepine or phenobarbital. Clin Neuropharmacol 1988; 11: 348-59
54. Bourgeois BF. Combination of valproate and ethosuximide: antiepileptic and neurotoxic interaction. J Pharmacol Exp Ther 1988; 247: 1128-32
55. Bourgeois BF. Antiepileptic drug combinations and experimental background: the case of phenobarbital and phenytoin. Naunyn Schmiebergs Arch Pharmacol 1986; 333: 406-11
56. Bourgeois BF, Wad N. Combined administration of carbamazepine and phenobarbital: effect on anticonvulsant activity and neurotoxicity. Epilepsia 1988; 29: 482-7
57. Bourgeois BFD. Important pharmacokinetic properties of antiepileptic drugs. Epilepsia 1995; 36 Suppl. 5: 1-7
58. Leach JP, Sills GJ, Majid A, et al. Effects of tiagabine and vigabatrin on GABA uptake into primary cultures of rat conical astrocytes. Seizure 1996; 5: 229-34
59. Cereghino JJ, Penry JK. Introduction. In: Levy RH, Mattson RH, Meldrum BS, editors. Antiepileplic drugs. 4th ed. New York: Raven Press, 1995: 1-11
60. Meunier H, Carraz G, Meunier Y, et al. Properictes pharmacodynamiques de lacide n-dipropylacetique. Therapie 1963; 18: 435-8
61. Stewart J, Hughes E, Kirker S, et al. Combined vigubultin and lamotrigine for very refractory epilepsy. Seizure 1992; 1 Suppl. A: 13-39
62. Brodie MJ, Yuen AWC and the 105 Study Group. Lamotrigine substitution study: evidence for synergism with sodium valproate. Epilepsy Res 1997; 26: 423-6
63. Richens A. Rational polypharmacy. Seizure 1995; 4: 211-4
64. Punuyiotopoulos CP, Ferric CD, Knoll C, et al. Interaction of lamotrigine and sodium valproate [letter]. Lancet 1993; 341: 445
65. Klitgaard H, Knudsen ML, Jackson HC. Synergism between drugs with different mechanisms of action against audiogenic seizures in DBA/2 mice [abstract]. Epilepsia 1993; 34 Suppl. 6: 93
66. Leach JP, Sills GJ, Thompson G, et al. The neurochemical effects of tiagahine and vigabatrin alone and in combination in mouse cortex. Gen Pharmacol 1997; 28: 715-9
67. Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of gahapeiuin in mouse brain. Epilepsy Res 1997; 27: 175-80
68. Petroff OAC, Rolhman DL, Behar KL, et al. The effect of gabapentin on brain GABA in patients with epilepsy. Ann Neurol 1996; 39: 95-9
69. Sills GJ, Leach JP, Butler E, et al. Neurochemical studies with topiramate in mouse brain [abstract]. Epilepsia 1997; Suppl. 3: 177
70. Sills GJ, Leach JP, Fraser CM, et al. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997; 325: 35-40
71. Leach JP, Sills GJ, Butler E, et al. Neurochemical actions of the desglycinyl metabolite of remacemide hydrochloride (ARL 12495AA) in mouse brain. Br J Pharmacol 1997; 121: 923-6
72. McKee PJW, Blacklaw J, Friel E, et al. Adjuvant vigabatrin in refractory epilepsy: a ceiling to effective dosage in individual patients? Epilepsia 1993; 34: 937-43
73. Grant SM, Heel RC. Vigabatrin: a review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in epilepsy and disorders of motor control. Drugs 1991; 41: 889-926
74. Swinyard EA, Woodhead JH, Wolf HH. Use of isobolograms in predicting drug interactions. In: Pitlick WH, editor. Antiepileptic drug interactions. New York: Publ Demos. 1989: 261-75
75. Mattson RH. Anticpileptic drug monitoring: a reappraisal. Epilepsia 1995; 36 Suppl. 2: 22-9
76. Ferrendelli JA. Rational polypharmacy. Epilepsia 1995; 36 Suppl. 2: 115-8